Lilly expands Zepbound vial options

New vial sizes and lower prices now available for self-pay patients

Eli Lilly and Company has launched 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, priced at $499 through the Zepbound Self Pay Journey Program. The program offers reduced pricing on first fills and refills made within 45 days. Lilly also lowered the price of the 2.5 mg and 5 mg vials, expanding access for self-pay patients via LillyDirect Self Pay Pharmacy Solutions. Zepbound is also available in six single-dose pen options, with recommended maintenance doses of 5 mg, 10 mg, or 15 mg once weekly.

How is Zepbound dosed and administered?

Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL doses in a single-dose pen. Patients begin with 2.5 mg for 4 weeks, then increase to a maintenance dose of 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.

What new Zepbound vial doses has Lilly launched?

Lilly has introduced 7.5 mg and 10 mg single-dose vials of Zepbound, expanding the range of vial options for self-pay patients.

How does the Zepbound Self Pay Journey Program work?

The program offers 7.5 mg and 10 mg vials at $499 for first fills and refills made within 45 days. Refills outside that window cost $599 and $699, respectively.

What are the updated prices for other Zepbound vials?

Lilly lowered the price of the 2.5 mg vial to $349 per month and the 5 mg vial to $499 per month.

Where can patients access these vial options?

All vial offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions, which removes third-party supply chain entities to offer transparent pricing.